perampanel Side Effects
Also known as: Fycompa
Analysis of 7,188 adverse event reports submitted to the FDA from 2012 to 2025.
Total Reports
7,188
Death-Related
453
6.3% of reports
Hospitalizations
2,745
38.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 453 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 95 |
| DRUG INEFFECTIVE | 56 |
| OFF LABEL USE | 45 |
| SEIZURE | 39 |
| MULTIPLE-DRUG RESISTANCE | 36 |
| SUDDEN UNEXPLAINED DEATH IN EPILEPSY | 32 |
| PNEUMONIA | 29 |
| CARDIAC ARREST | 26 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 26 |
| PNEUMONIA ASPIRATION | 24 |
| STATUS EPILEPTICUS | 24 |
| RESPIRATORY FAILURE | 23 |
| COMPLETED SUICIDE | 22 |
| SEPTIC SHOCK | 19 |
| TOXICITY TO VARIOUS AGENTS | 19 |
| CONDITION AGGRAVATED | 17 |
| SEPSIS | 16 |
| PRODUCT USE IN UNAPPROVED INDICATION | 15 |
| AGGRESSION | 14 |
| EPILEPSY | 14 |
Reactions in Hospitalization Reports
Top reactions in 2,745 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 401 |
| SEIZURE | 376 |
| OFF LABEL USE | 282 |
| SOMNOLENCE | 226 |
| AGGRESSION | 188 |
| STATUS EPILEPTICUS | 186 |
| EPILEPSY | 158 |
| SUICIDE ATTEMPT | 151 |
| INTENTIONAL OVERDOSE | 145 |
| DRUG INTERACTION | 144 |
| DIZZINESS | 138 |
| FALL | 126 |
| FATIGUE | 112 |
| PNEUMONIA | 104 |
| TOXICITY TO VARIOUS AGENTS | 99 |
| HOSPITALISATION | 98 |
| PYREXIA | 98 |
| CONDITION AGGRAVATED | 93 |
| PNEUMONIA ASPIRATION | 84 |
| VOMITING | 81 |
Nearby — Related Medications
What the FAERS Data Reveals About perampanel Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 7,188 voluntary reports linked to perampanel and its brand equivalents (Fycompa), spanning 2012 through 2025. Of those, 453 (6.3%) listed death as an outcome and 2,745 (38.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 54% were female and 46% male; age distribution skews toward 18-44, with 2,072 reports in that bracket. The single most reported reaction is seizure with 1,098 submissions, followed by drug ineffective and off label use.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.